ASCT in DLBCL – is it over?

Lymphoma Hub
03/08/2022 17 min
ASCT in DLBCL – is it over?

Listen "ASCT in DLBCL – is it over?"

Descargar episodio Ver en sitio original

Episode Synopsis

As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem cell transplant in the treatment of diffuse large B-cell lymphoma. Many steering committee members felt that this therapy no longer plays an important role in treatment of the disease. Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast Lymphoma Hub

ASH 2025 | Key highlights in lymphoma and CLL 22/12/2025
ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL 18/12/2025
What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? 17/12/2025
ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL 11/12/2025
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL 10/12/2025
ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity 10/12/2025
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial 05/12/2025
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? 05/11/2025
Latest updates from the phase III STARGLO trial: 2L and 3L+ data 15/10/2025
Symposium | Customizing therapy for MCL: Q&A 04/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA